Miquel Sans CuffíMiquel Sans Cuffí

Miguel Sans Cuffi

HEAD OF SERVICE

Professional Details

Centro Médico Teknon
HEAD OF SERVICE
January 2023 - Present
I6T-MC-AMAM - CMTKN - 2018-004614-18. Phase 3, multicenter, randomized, double-blind, comparative study with a...
Lilly
APD334-303 - CMTKN - 2018-003987-29. An open-label extension study of Etrasimod in subjects with moderate ulcerative colitis...
Arena Pharmaceuticals
ABX464-104 - CMTKN - 2019-000733-39. Open-label, phase IIb study of the efficacy and safety of ABX464 as maintenance therapy...
Abivax
RPC01-3203 - CMTKN - 2017-004294-14. Induction study: Phase 3, multicenter, randomized, double-blind study...
Celgene
ABX464-103 - CMTKN - 2018-003558-26 . A randomized, double blind, placebo controlled, parallel group, multiple dose, induction study t...
Abivax
PBF-677-3 - CMTKN - 2017-003228-54. Randomized, double-blind, multicenter phase IIa (proof of concept) clinical trial...
Palobiofarma
0173 - CMTKN - 2018-001272-37. Phase II, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy...
Theravance Biopharma
0157 - CMTKN - 2018-002136-24. A Phase 2b/3 multicenter, randomized, double-blind, multidose, placebo-controlled trial...
Theravance Biopharma
RPC01-3204 - CMTKN - 2017-004295-55. Multicenter, unblinded, phase 3 extension study evaluating ozanimod...
Celgene
RPC01-3202 - CMTKN - 2017-004293-33. Induction study, phase 3, multicenter, randomized, double-blinded study...
Celgene
SHP647-307 - CMTKN - 2017-000617-23. Phase 3, randomized, double-blind, placebo-controlled, parallel-group study for...
Shire Pharmaceuticals
APD334-301 - CMTKN - 2018-003985-15. A 52-week, randomized, double-blind, placebo-controlled, phase 3 study to evaluate...
Arena Pharmaceuticals
Make an appointment with this professional